Japanese encephalitis vaccine and its preparation method and application

By developing the E-recombinant protein of B encephalitis and its preparation method, the problem of lack of WHO certification of primary cell matrix of gophal kidney in the existing B encephalitis vaccine was solved. The E-recombinant protein of B encephalitis E-recombinant protein 1 and E were recombinant in the prepared B encephalitis B encephalitis The protein 2 vaccine has high immune effect, especially the E recombinant protein 2 shows better immunogenicity and stability, which is suitable for large-scale promotion and application.

CN116554358BActive Publication Date: 2024-11-15BEIJING WANJIARUI BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310754710.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-26
Publication Date
2024-11-15
Estimated Expiration
2043-06-26

AI Technical Summary

Technical Problem

The existing type B encephalitis vaccine lacks WHO certification, which leads to its limited application and urgently needs to develop a new type B encephalitis vaccine.

Method used

Develop E-recombinant protein of B encephalitis and its preparation method, provide E-recombinant protein 1 and E-recombinant protein 2, express and purify through the insect baculovirus expression system, enhance its immunogenicity and prepare subunit vaccines .

Benefits of technology

The expression and solubleness of E recombinant protein in B encephalitis were improved, and the vaccine prepared had good immune effects, especially E recombinant protein 2 showed higher immunogenicity and stability, which was suitable for large-scale promotion and application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116554358B_ABST
    Figure CN116554358B_ABST
Patent Text Reader

Abstract

The present invention discloses a Japanese encephalitis E recombinant protein, wherein the Japanese encephalitis E recombinant protein includes Japanese encephalitis E recombinant protein 1 and Japanese encephalitis E recombinant protein 2, wherein the amino acid sequence of the Japanese encephalitis E recombinant protein 1 is shown in SEQ ID NO.1, and the amino acid sequence of the Japanese encephalitis E recombinant protein 2 is shown in SEQ ID NO.3. The present invention also discloses a Japanese encephalitis subunit vaccine, wherein the vaccine contains the Japanese encephalitis E recombinant protein 1 or the Japanese encephalitis E recombinant protein 2. The Japanese encephalitis E recombinant protein 1 and the Japanese encephalitis E recombinant protein 2 prepared by the present invention both have good immunogenicity, and the Japanese encephalitis E recombinant protein 2 has better immunogenicity than the Japanese encephalitis E recombinant protein 1. Therefore, the two Japanese encephalitis E recombinant proteins disclosed in the present invention can be used as important candidate antigens for Japanese encephalitis subunit vaccines, providing important reference and reference for the research and development of Japanese encephalitis subunit vaccines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a Japanese encephalitis vaccine and a preparation method and application thereof. Background Art

[0002] Epidemic encephalitis B, also known as Japanese encephalitis B, is an acute mosquito-borne viral infectious disease caused by the Japanese encephalitis virus (JEV) of the Flaviviridae family. The peak incidence is from July to September when mosquitoes breed. JE was first discovered in Japan. The disease was not clinically recognized until 1871. JE is a major epidemic disease that causes serious harm to the pig farming industry. It mainly affects the reproductive performance of sows, such as miscarriage, stillbirth and mummified fetuses in pregnant sows, orchitis in boars, and can cause persistent high fever in adult pigs and fattening pigs, leading to encephalitis in newborn piglets.

[0003] In 1935, Japanese scholars isolated JEV for the first time. In 1940, China isolated JEV. JEV belongs to the Flaviviridae family and the Flavivirus genus, which contains more than 70 viruses, the most important of which are the yellow fever virus (YFV), JEV, West Nile virus (WNV) and dengue virus (DV) that cause human disease. JEV is divided into three serotypes: JaGAr, Nakayama and Mie (Intermediate Type), and their biological characteristics (including growth characteristics and virulence) are different.

[0004] JEV is a single-stranded positive-strand RNA virus with a genome length of 11kb. The genome structure is shown in the figure below ( Figure 2 ), JEV encodes at least three structural proteins: core protein (C), membrane protein (pr M / M) and envelope glycoprotein (E). The hydrophobic amino acids at the C-terminus of the C protein temporarily fix it on the rough endoplasmic reticulum membrane of the host cell, which helps it to assemble into a nucleocapsid that encapsulates the genome and protects it from damage by nucleases. The precursor protein of the M protein, Pr M, is essential for the correct folding, localization on the membrane and final assembly of the E protein. The E protein, the main structural protein, is the most important component on the surface of the virus particle. It is closely related to the adsorption, penetration, pathogenicity and induction of host immune response of the virus.

[0005] At present, the prevention and control of JEV mainly rely on inactivated vaccines and live vaccines, such as hamster kidney cell inactivated vaccine and hamster kidney cell attenuated live vaccine. However, due to the lack of WHO certification for the hamster kidney primary cell matrix, the vaccine is currently mainly used in my country and South Korea. Therefore, it is urgent to develop a new type of Japanese encephalitis vaccine. Summary of the invention

[0006] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide a Japanese encephalitis Japanese encephalitis E recombinant protein and a preparation method and application thereof.

[0007] Therefore, on one hand, the present invention provides a recombinant protein, which is a Japanese encephalitis E recombinant protein. The Japanese encephalitis E recombinant protein includes Japanese encephalitis E recombinant protein 1 and Japanese encephalitis E recombinant protein 2. The amino acid sequence of the Japanese encephalitis E recombinant protein 1 is shown in SEQ ID NO.1, and the amino acid sequence of the Japanese encephalitis E recombinant protein 2 is shown in SEQ ID NO.3.

[0008] Preferably, the Japanese encephalitis E recombinant protein 2 of the present invention consists of a B cell antigen epitope, an antigen epitope binding to MHC class I molecule, aa3 to aa400 of Japanese encephalitis E recombinant protein 1, an antigen epitope inducing IFN-γ, a 6His tag and a linker.

[0009] Preferably, the amino acid sequence of the B cell antigen epitope described in the present invention is SEKIFEIRFETNDK KS.

[0010] Preferably, the amino acid sequence of the antigen epitope binding to MHC class I molecules described in the present invention is YT YNFDFDY.

[0011] Preferably, the amino acid sequences of the antigenic epitopes inducing the production of IFN-γ described in the present invention are LKPLKFNTE.

[0012] Preferably, the amino acid sequences of the linkers described in the present invention are GGGGSGGGGS.

[0013] In yet another aspect, the present invention also provides a Japanese encephalitis subunit vaccine, wherein the vaccine contains the Japanese encephalitis E recombinant protein 1.

[0014] In yet another aspect, the present invention also provides a Japanese encephalitis subunit vaccine, wherein the vaccine contains the Japanese encephalitis E recombinant protein 2.

[0015] The Japanese encephalitis E recombinant protein 1 and the Japanese encephalitis E recombinant protein 2 prepared by the present invention both have good immunogenicity, and the Japanese encephalitis E recombinant protein 2 has better immunogenicity than the Japanese encephalitis E recombinant protein 1. Therefore, the two Japanese encephalitis E recombinant proteins disclosed in the present invention can be used as important candidate antigens for Japanese encephalitis subunit vaccines, providing important reference and reference for the research and development of Japanese encephalitis subunit vaccines. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1Analysis results of the transmembrane region of Japanese encephalitis E protein. Inside represents the intracellular region. The larger the inside value, the more likely it is that the amino acid is located in the intracellular region; Outside represents the extracellular region. The larger the outside value, the more likely it is that the amino acid is located in the extracellular region; Transmembrane represents the transmembrane region. The larger the Transme mbrane value, the more likely it is that the amino acid is in the transmembrane region.

[0017] Figure 2 SDS-PAGE image of Japanese encephalitis E recombinant protein 2, wherein 1 is the purified Japanese encephalitis E recombinant protein 2. DETAILED DESCRIPTION

[0018] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0019] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0020] Example 1: Preparation of Japanese encephalitis E recombinant protein

[0021] 1.1 Preparation of Japanese encephalitis E recombinant protein 1

[0022] We selected an E protein of a strain isolated and identified in recent years from NCBI (GenBank: UQR78754.1) and analyzed its transmembrane region. The results are as follows: Figure 1 As shown, the N-terminal 450 amino acids are the extracellular region, therefore, the N-terminal 451-500 amino acids are removed, and the remaining 450 amino acids of the protein (shown in SEQ ID NO.1, to distinguish the subsequent recombinant proteins, it is named Japanese encephalitis E recombinant protein 1) are prepared for recombinant protein (a 6His tag is added to the C-terminus during preparation to facilitate purification).

[0023] The conventional insect baculovirus expression system was used to express the Japanese encephalitis E recombinant protein 1. The brief description is as follows:

[0024] The codon-optimized Japanese encephalitis E recombinant protein 1 nucleotide sequence (shown in SEQ ID NO.2) was selected as a template, and BamHI and XhoI restriction sites and 6His tags were inserted, and then the target gene and vector pFastBac1 were double-digested and connected. The ligation product was transformed into E. coli DH5α competent cells, positive bacteria were selected for amplification and culture, and the recombinant plasmid (pFastBac1-E1) was extracted. The positively identified recombinant plasmid was added to E. coli DH10Bac competent cells for transposition, and white spot bacteria were selected for identification and culture to obtain recombinant Bac mid. Under the action of transfection reagent Cellfectin ReagentⅡ, Sf9 insect cells were transfected to obtain recombinant baculovirus seed virus.

[0025] The Bac-PEDV-E1 virus solution was inoculated into the cell suspension and inoculated into SF9 cells in good growth state (confluence>80%) at a ratio of MOI=1. The cells were shaken and cultured at 28°C and 120rpm for 96 hours. If the cells showed obvious lesions (the cells became larger and rounder), the cell culture medium was collected and centrifuged at 6000r / min and 4°C for 10 minutes, and the supernatant was taken for later use; the protein was purified by nickel column, gradient eluted with 400mM imidazole solution, and the eluate was collected; after dialysis and replacement of the solution, it was sterilized by 0.22μm filter membrane and stored at -80°C for later use.

[0026] After the above steps, although the Japanese encephalitis E recombinant protein 1 can be successfully prepared and purified, the yield is low (<50 mg / L) and the solubility is poor. Therefore, the application of Japanese encephalitis E recombinant protein 1 in Japanese encephalitis vaccines is limited (high cost and poor stability of the prepared vaccine). Therefore, based on this work, the researchers conducted further research and analysis on Japanese encephalitis E recombinant protein 1.

[0027] 1.2 Preparation of Japanese encephalitis E recombinant protein 2

[0028] On the basis of Japanese encephalitis E recombinant protein 1, the protein was further truncated through software analysis and actual expression verification, first removing 2 amino acids at the N-terminus, and then removing 50 amino acids at the C-terminus (i.e. retaining aa3 to aa400 of Japanese encephalitis E recombinant protein 1); at the same time, in order to enhance the immunogenicity of the recombinant protein, a B cell antigen epitope (amino acid sequence of SEKIFEIRFETNDKKS) and an antigen epitope binding to MHC class I molecules (amino acid sequence of YTYNFDFDY) were added to the N-terminus, and an antigen epitope inducing the production of IFN-γ (amino acid sequence of LKPLKFNTE) and a 6His tag were added to the C-terminus, which was connected to the main protein with a linker (amino acid sequence of GGGGSGGGGS). The designed protein was named Japanese encephalitis E recombinant protein 2, and its amino acid sequence is shown in SEQ ID NO.3.

[0029] The Japanese encephalitis E recombinant protein 2 was prepared using the insect baculovirus system according to the method in 1.1. The nucleotide sequence after codon optimization is shown in SEQ ID NO. 4. The SDS-PAGE purity of the Japanese encephalitis E recombinant protein 2 prepared by this method can reach more than 90% ( Figure 2 As shown), SDS-PAGE molecular weight ( Figure 2 As shown in the figure, the expression level of Japanese encephalitis E recombinant protein 2 in this system can reach 100-150 mg / L (slightly larger than predicted, due to partial glycosylation); after calculation, the expression level of Japanese encephalitis E recombinant protein 2 in this system can reach 100-150 mg / L, and it has good solubility and can be dissolved using conventional PBS buffer. Therefore, Japanese encephalitis E recombinant protein 2 has higher expression yield and better solubility than Japanese encephalitis E recombinant protein 1, and has better advantages in preparing subunit vaccines.

[0030] Example 2: Preparation of Japanese encephalitis subunit vaccine

[0031] The Japanese encephalitis E recombinant protein 1 and Japanese encephalitis E recombinant protein 2 prepared in Example 1 were diluted to 100 μg / ml, and 200 ml of the diluted recombinant protein were taken respectively, and the vaccine was prepared by emulsification with ISA 201VG adjuvant (purchased from France Sepic Company) at a mass ratio of 1:1. Each batch of vaccine prepared about 400 ml of vaccine, wherein the concentration of Japanese encephalitis E recombinant protein 1 or Japanese encephalitis E recombinant protein 2 in the vaccine was about 50 μg / ml. According to the current appendix of the Chinese Veterinary Pharmacopoeia, the test results of the two groups of vaccines met the requirements. The qualified vaccines were stored at 2-8°C for standby use.

[0032] Example 3: Comparative study with market vaccines

[0033] 3.1 Safety Test

[0034] The two groups of prepared vaccines (experimental groups) and the commercially available attenuated vaccine (produced by Wuhan Keqian Biological, made from the porcine Japanese encephalitis live vaccine SA-14-14-2 strain, which is commercially available) were used to immunize 30-45 week old piglets, 5 pigs in each group, and 4.0 ml of the corresponding vaccine was injected into the neck muscle of each pig. After the injection, the body temperature was checked every day for 7 consecutive days; and the health status of the pigs was observed every day for 14 consecutive days.

[0035] The results showed that the safety of the three groups of vaccines were all qualified. After injection, the body temperature remained stable (all between 38.9℃ and 39.6℃). During the 14 days of observation, the pigs' spirits and appetite were normal, and no abnormalities were found. There were no abnormalities visible to the naked eye at the injection sites (such as swelling, nodules, ulcers, etc.).

[0036] 3.2 Efficacy test

[0037] The two groups of vaccines (test groups) prepared and the commercially available attenuated vaccine (produced by Wuhan Keqian Biological, made from the live porcine Japanese encephalitis vaccine SA-14-14-2 strain, commercially available) were used to immunize 30-45 week old piglets, 5 in each group, 2.0 ml of the two groups of test vaccines were injected into the neck muscle of each piglet (the control vaccine was immunized with one dose according to the instructions), and 5 non-immunized piglets were set up as the control group at the same time, and the second immunization was performed 2 weeks after immunization by the same route and dose. Blood was collected before immunization, before the second immunization, and 14 days after the second immunization for neutralizing antibody detection.

[0038] The results showed that the neutralizing antibody titers of the three vaccine immunization groups before the second immunization (14 days after the first immunization) were basically the same; however, on the 14th day after the second immunization, the neutralizing antibody of the Japanese encephalitis E recombinant protein 1 vaccine group was basically the same as that of the control vaccine group, while the neutralizing antibody of the Japanese encephalitis E recombinant protein 2 vaccine group was higher than that of the other two immunization groups. This shows that the Japanese encephalitis E recombinant protein 1 and Japanese encephalitis E recombinant protein 2 prepared by the present invention both have good immune effects, and the Japanese encephalitis E recombinant protein 2 has a better immune effect and is suitable for large-scale promotion and application. The results are shown in Table 1.

[0039] Table 1 Neutralizing antibody detection results after immunization

[0040]

[0041] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A recombinant protein, the recombinant protein is Japanese encephalitis E recombinant protein 2, characterized in that: The amino acid sequence of the Japanese encephalitis E recombinant protein 2 is shown in SEQ ID NO.

3.

2. A Japanese encephalitis subunit vaccine, characterized in that: The vaccine contains the Japanese encephalitis E recombinant protein 2 according to claim 1.